Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Jollibee Plans U.S. Listing for International Business, Shares Rally 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
WORCESTER, Mass., April 05, 2016 -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers, announced today that Timothy P. Coleman, President and Chief Executive Officer, will present a corporate overview and update at the Needham & Company’s 15th Annual Healthcare Conference on April 12-13, 2016 in New York City. The Nemucore presentation will take place at 09:20 AM on Wednesday, April 13, 2016.
About Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers. Nemucore's most advanced candidate NMI-900, a potential "best-in-class" therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in late-2016. Two additional candidates are anticipated to enter clinical trial development later in 2017, targeting a variety of difficult-to-treat oncology indications, including breast, non-small cell lung cancer (NSCLC), myelodysplastic syndrome (MDS) and other cancers. For more information, please visit our website at www.Nemucore.com.
Contacts: Tim Coleman (investors) Nemucore Medical Innovations (508) 762-1017 BCC Partners (media) Karen L. Bergman (650) 575-1509 [email protected] Jen LaVin (207) 360-0473 [email protected]
